Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in R/R DLBCL?

How will front-line use of polatuzumab vedotin influence patient outcomes in DLBCL?Подробнее

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCLПодробнее

Using Novel Therapy in Relapsed-Refractory DLBCLПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma.Подробнее

Glofitamab and polatuzumab vedotin in DLBCLПодробнее

A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCLПодробнее

Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?Подробнее

Improving outcomes for R/R DLBCL with polatuzumab vedotinПодробнее

ADC polatuzumab vedotin in combinations for relapsed lymphomaПодробнее

Why Combine Mosunetuzumab and Polatuzumab Vedotin?Подробнее

Polatuzumab vedotin plus rituximab and lenalidomide in DLBCL: a Phase Ib/II studyПодробнее

Dr. Herrera Discusses Polatuzumab Vedotin in DLBCLПодробнее

Clinical implications of the ODAC vote in favor of polatuzumab vedotin for untreated DLBCL.Подробнее

LOTIS-2: R/R DLBCL patient characteristics impact DoR to loncastuximab tesirineПодробнее

POLARIX: Polatuzumab vedotin and R-CHP superior to R-CHOP in DLBCLПодробнее

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCLПодробнее

Dr. Hou on Polatuzumab Vedotin in DLBCLПодробнее

What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?Подробнее